Product Compliance And Certification For Infant Formula In The USA

First classify the product and its intended infant

Under FD&C Act section 201(z), infant formula is food represented as resembling human milk or suitable as its complete or partial substitute for an infant (not more than 12 months old). Marketing names alone do not decide the route. Distinguish standard formula for healthy term infants from a medically indicated “exempt infant formula” under 21 CFR 107.3 and 107.50; exempt does not mean free of oversight. A toddler beverage or ordinary complementary food must be assessed against its actual intended use and claims—not automatically placed in the infant-formula regime.

Medical-use (exempt) formulas require a separate route check: 21 CFR 107.50 distinguishes products generally sold at retail from those generally supplied by prescription or to institutions. Both have specific submissions, labeling and quality obligations; only individually justified deviations are available. Do not automatically apply the ordinary new-formula filing sequence or its nutrient/CGMP requirements unchanged to every exempt product. 21 CFR §107.50

Exempt-formula timing is different: §107.50(b)(3), applied also to qualifying nonretail formulas through §107.50(c)(4), requires the label and other labeling, full quantitative formulation, and description of the medical conditions to reach FDA at least 90 days before first processing for commercial or charitable distribution. That is a pre-production submission, not the §106.120 premarketing clock. Supply to a hospital does not itself establish the nonretail category if the same formulation is generally sold at retail (§107.50(c)(1)). A formula individually prepared for identified infants at a physician’s request is treated separately under §107.50(c)(6); do not extrapolate this exception to a commercial SKU.

• Record intended ages, feeding role (sole, partial, supplement), front-panel claims and instructions.
• Identify whether the product is standard, low-birth-weight, metabolic or other medically specialised formula; justify any exempt status.
• Specify powder, ready-to-feed liquid or liquid concentrate; packaging and processing hazards differ.
• Record every manufacturing/packing location, responsible brand owner, U.S. distributor and any overseas producer.

U.S. infant-formula route matrix: which layer applies?

Also determine whether the general food-safety CGMP and hazard-analysis/preventive-control provisions of 21 CFR part 117 apply to the actual facility and operations; part 106 does not by itself resolve every overlapping food-law obligation. Separately assess 21 CFR parts 113/114 only for products meeting their processing definitions. FDA: 21 CFR Part 117

Read every Part 106 nutrient, manufacturing or microbiological row together with the §107.50 classification gate: these obligations apply to exempt formulas only to the extent imposed by their applicable exempt-formula conditions, not automatically in the same way as to nonexempt formulas.

Build evidence for the actual formulation and factory

The document set must relate to the formula and manufacturing process actually sold, not a generic facility certificate. The following is a practical evidence-control bundle; the precise required studies and records depend on the product and process.

• Version-controlled quantitative recipe; U.S. per-100-kcal nutrient specification; ingredient and food-contact regulatory assessments.
• Supplier qualification, batch traceability and certificates/testing for sensitive premixes, oils, powders, cans and closures.
• Quality-factor justification for normal physical growth and protein quality, including study or exemption rationale as applicable.
• Nutrient sampling at appropriate manufacturing stages, stability through the “use by” date, and batch-release records.
• For powder: production-aggregate sampling for Cronobacter spp. and Salmonella spp. under 21 CFR 106.55, alongside preventive controls.
• Validated manufacturing controls, deviations/CAPA, complaints, recall and distribution tracing; evidence tied to each plant.

Registration, 90-day submission and production verification

A new infant formula includes one affected by a major change in formulation or processing. The responsible manufacturer must distinguish three separate submissions; a food-facility registration number, a third-party audit and an FDA file acknowledgement are not substitutes. The 90-day rule is a premarket-notification requirement, not a guaranteed FDA approval date.

For a nonexempt new formula, the 90 days run from the FDA filing date of a complete §106.120 submission, not from mailing an incomplete package. FDA may assign a new filing date after a substantive amendment (§106.120(e)–(f)). A manufacturer making infant formula for the first time can trigger the new-formula route even without changing another company’s recipe (§412(c)(2)). The separate exempt-formula pathway must instead be assessed under §107.50. 21 CFR §106.120

1. Before marketing: register the new infant formula and intended manufacturing establishments with FDA under §106.110.
2. At least 90 days before marketing: file the new-formula submission under §106.120 with formulation, change description, nutrient/quality-factor and CGMP assurances.
3. After the first production and before interstate distribution: send the written verification under §106.130, including final-product nutrient results and manufacturing assurances.
4. Before shipment: confirm submissions are adequate, answer FDA questions, close quality or label gaps and document the release decision.

U.S. label and package: checks before printing

A compliant European, UK or Canadian carton is not automatically a compliant U.S. carton. Part 107 has infant-formula-specific rules, beyond ordinary food labeling. Review artwork against the formula as prepared, including mixing risks.

• Nutrient table and energy basis in the units and sequence required by 21 CFR 107.10, including the applicable iron statement.
• Directions for storage, preparation, water/dilution where relevant, preparation pictogram and caution on incorrect use under §107.20.
• Use-by date supported by nutrient stability and quality data; lot identifier and recall traceability.
• Ingredients and applicable allergen declarations, net quantity, name/address statements and truthful, non-misleading claims.
• Container/closure safety and form-specific front-panel “Add Water” or “Do Not Add Water” statements where required.
• Check for the physician-consultation statement required by §107.20(f), subject to any properly supported, product-specific deviation under §107.50.

Imported formula: a separate border and importer gate

Foreign manufacture does not displace U.S. formula rules. Commercial imports must be checked for FDA food-facility registration (distinct from formula registration), prior notice and entry compliance; determine who is the FSVP importer under 21 CFR part 1, subpart L and whether any exemption actually applies. Dairy-derived products may involve additional agriculture admissibility checks. A special 2022 enforcement-discretion letter is not a transferable permission for a new product or supplier.

• Match the legal manufacturer and actual plant to the formula submission, product codes, label and shipment documents.
• Assign the U.S. owner/consignee, FSVP importer where applicable, and party responsible for prior notice and customs entries; do not conflate roles.
• Check current FDA import alerts, detention exposure, recall status, temperature/lot integrity and the exact formula SKU before purchase orders.

Changes, supply incidents and a defensible release decision

Create change control that asks whether a switch in oil supplier, nutrient premix, protein source, heat treatment or production plant is a “major change” needing a new-formula submission. For less obvious changes, document the regulatory assessment rather than assume exemption; quality-system or labeling updates may still be necessary. Regulatory texts, not voluntary certifications such as ISO, determine mandatory entry conditions.

There is another filing gate even where a change is not classified as “major”: if a change to the formulation or processing may affect whether the formula is adulterated, §106.140 requires a submission before the first processing of the changed formula. Document both the §106.120 major-change decision and this separate §106.140 trigger. 21 CFR §106.140

For an exempt formula, assess §107.50(b)(4) and (c)(4) separately: ingredient or process changes that may adversely affect nutrient levels or nutrient availability require specified information to FDA before first processing. Do not assume a §106.140 analysis replaces the exempt-formula change route.

• Freeze intended-use classification, U.S. recipe and U.S. artwork in the same controlled version.
• Check each proposed input/process/plant change against §106.3 and the submission/quality requirements.
• Hold affected lots for investigation if testing, environmental monitoring or supplier incidents create a safety question; maintain traceability and recall readiness.
• Release only after an accountable reviewer signs off the product, plant, nutrient, safety, label, submission and import gates.

What is changing in 2026—and what has not changed

The FDA’s 2025–2026 Operation Stork Speed work includes a nutrient-standards review and expanded contaminant monitoring; these initiatives must not be described as already-effective replacement nutrient limits. FDA’s July 2026 communication also emphasises supplier-origin hazards in powder ingredients. Recheck current law, official alerts and any future final rules at the point of formulation freeze and again before the first commercial shipment.

Related market routes and primary sources

This page owns the U.S. product-specific cross-regime route. It does not reproduce other countries’ notification systems or market-specific formulas:

• infant-formula compliance route in the UK
• infant-formula compliance route in Canada

Primary legal and FDA sources

• FDA infant formula registration and submissions
• FDA regulatory route and verification
• 21 CFR part 106: controls and filings
• 21 CFR part 107: labels and nutrients
• FDA importing and FSVP overview
• FDA 2026 infant formula industry updates

Scope: U.S. federal product-route map for commercial or charitable infant-formula distribution. Product-specific legal assessment, FDA correspondence and importer due diligence may change the route; no universal “FDA certification” is issued for formula.